Biodesix

Biodesix

Biodesix runs corporate and laboratory facilities in Louisville, Colorado, with an additional lab in De Soto, Kansas. The company commercializes blood-based diagnostic tests that address immediate clinical questions in lung disease, including risk stratification for pulmonary nodules and treatment guidance for non-small cell lung cancer. Its reference laboratory performs proteomic analysis through MALDI-ToF mass spectrometry and genomic testing via next-generation sequencing, generating reports that physicians use to rule out malignancy or select therapies. The company generates revenue across two integrated lines: clinical diagnostic testing services, where it sells directly to ordering physicians and hospital systems, and biopharmaceutical development services, where it provides companion diagnostic development and testing for pharmaceutical partners running clinical trials. The test menu includes Nodify XL2 and Nodify CDT for lung nodule evaluation, and VeriStrat and GeneStrat for treatment selection in advanced lung cancer. Biodesix participates across the continuum from early diagnosis through late-stage therapy guidance. Biodesix is a publicly listed company on the Nasdaq under ticker BDSX, following its merger with a special purpose acquisition company in 2021. The firm maintains its primary CLIA-certified, CAP-accredited laboratory at its Colorado headquarters, with a secondary facility in Kansas supporting testing operations. Its laboratory infrastructure positions it as a central lab for biopharma clinical trials requiring molecular and proteomic biomarker testing. Biodesix differs structurally from a clinical lab aggregator or a pure-play diagnostics manufacturer. Its dual commercial model — pairing a physician-facing test menu with a biopharma services engine that develops and validates companion diagnostics — creates a feedback loop between clinical utility data and drug-development partnerships that most independent labs cannot replicate.